- Home
- MPV vs KZIA Comparison
MPV vs KZIA Comparison
Compare MPV & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPV | KZIA |
|---|---|---|
| Founded | 1988 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 154.5M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | MPV | KZIA |
|---|---|---|
| Price | $17.02 | $12.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 22.7K | ★ 252.2K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.05 | $4.86 |
| 52 Week High | $20.58 | $17.40 |
Technical Indicators
Market Signals| Indicator | MPV | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 43.25 |
| Support Level | $16.18 | $11.39 |
| Resistance Level | $17.57 | $14.79 |
| Average True Range (ATR) | 0.52 | 1.22 |
| MACD | 0.11 | -0.20 |
| Stochastic Oscillator | 95.67 | 1.75 |
Price Performance
Historical ComparisonAbout MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.